Achillion Pharmaceuticals, Inc. (ACHN) financial statements (2020 and earlier)

Company profile

Business Address 300 GEORGE STREET
NEW HAVEN, CT 06511
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 50300364459153122
Cash and cash equivalents 504377827433
Short-term investments  2572873787988
Receivables 121210
Prepaid expense 000000
Income taxes receivable0
Other undisclosed current assets 224217112
Total current assets: 275304383463155125
Noncurrent Assets
Property, plant and equipment 233221
Long-term investments and receivables  3128  36
Long-term investments  3128  36
Restricted cash and investments 000000
Deferred costs     00
Other noncurrent assets 0000  
Total noncurrent assets: 234312238
TOTAL ASSETS: 278338414465157162
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 121314141410
Accounts payable 257465
Accrued liabilities 9771065
Employee-related liabilities     11
Debt 000000
Other undisclosed current liabilities     (1)(1)
Total current liabilities: 12131415139
Noncurrent Liabilities
Long-term debt and lease obligation  00000
Long-term debt, excluding current maturities  00000
Liabilities, other than long-term debt 000   
Deferred revenue and credits00   
Deferred rent credit 0
Total noncurrent liabilities: 000000
Total liabilities: 12131415139
Stockholders' equity
Stockholders' equity attributable to parent 266325399450143153
Common stock 000000
Common stock, share subscribed but unissued, subscriptions receivable     (6) 
Additional paid in capital 939927917905600535
Accumulated other comprehensive income (loss) (0)(0)0(0)(0)0
Accumulated deficit (673)(603)(517)(456)(451)(382)
Total stockholders' equity: 266325399450143153
TOTAL LIABILITIES AND EQUITY: 278338414465157162

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Gross profit:   1566  
Operating expenses (76)(90)(80)(81)(69)(59)
Operating loss: (76)(90)(65)(15)(69)(59)
Nonoperating income
(Investment Income, Nonoperating)
 643101
Interest and debt expense (0)(0)(0)(0)(0)(0)
Loss from continuing operations before income taxes: (70)(85)(62)(14)(69)(59)
Income tax expense     (30) 
Net loss: (70)(85)(62)(14)(99)(59)
Other undisclosed net income attributable to parent    930 
Net loss available to common stockholders, diluted: (70)(85)(62)(5)(69)(59)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (70)(85)(62)(14)(99)(59)
Other comprehensive income (loss) 0(1)0(0)(0)(0)
Comprehensive loss: (70)(86)(62)(14)(99)(59)
Other undisclosed comprehensive income, net of tax, attributable to parent    930 
Comprehensive loss, net of tax, attributable to parent: (70)(86)(62)(5)(69)(59)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: